Clinical Trial
2022-000624-37 Recruiting, Active
CLOSE-3
A Phase 3, multicenter, randomized, evaluator-blinded clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic nanoemulsion, 0.05% compared to Prednisolone acetate, 1% in the treatment of inflammation after cataract surgery in pediatric population 0 to 3 years of age (CLOSE-3)”. CLOBOF3-17IA03 (CLOSE-3).
Disease
Disease type
Paediatric clinical trials
Patient type
Adult
Children
Funding
private
Members involved
Others investigators
Dr Marta Morales Ballús
Representative
Spain
Anterior Segment Rare Eye Diseases (WG4), CPMS & Digital Medecine (TWG10), Genetic Diagnostics (TWG6), National Integration (TWG9), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8)
Dr Susana Noval
Representative
Spain
Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader
ERN EYE member investigating site
HCP : Principal investigators
Hospital Sant Joan de Déu, Spain
Adress
Passeig de Sant Joan de Déu, 2
8950 Esplugues de Llobregat, Barcelona
Spain
Hospital Universitario La Paz, Spain
Adress
Paseo de la Castellana, 261
28046 Madrid
Spain